Abu Dhabi is set to become a global hub for pharmaceutical and life sciences distribution after key players in the sector signed a deal to advance this goal.
During the BIO International Convention 2024, The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Abu Dhabi Investment Office (ADIO), Etihad Airways and AD Ports Group have signed a landmark Memorandum of Understanding (MoU) to strengthen Abu Dhabi's position as a global pharmaceutical and life sciences distribution hub, leveraging its location, investment opportunities and advanced logistics capabilities.
In a statement, the group said in line with the Abu Dhabi Economic Vision 2030, the MoU is a pivotal step in Abu Dhabi's ongoing efforts to become a leading healthcare destination worldwide.
The strategic partnership aims to create attractive value propositions for pharmaceutical, biotechnology, and medical technology companies to establish their operations in Abu Dhabi.
"Leveraging Abu Dhabi's strategic location at the gateway to the MENA region, we are pleased to partner with world-class leaders in investment and logistics, offering advanced infrastructure with easy access to regional and global markets. This MoU reaffirms DoH's commitment to leading the transformation of the regional healthcare ecosystem," said Asma Ibrahim Al Mannaei, executive director of the Research and Innovation Centre at DoH.
"Our vision is to create a healthcare environment where patients have access to the latest treatments and medical technologies."
"The establishment of this distribution hub will not only solidify Abu Dhabi's position as a critical player in the global pharmaceutical industry but also drive economic growth," he added.
As part of the agreement, the entities will work together to ensure timely access to innovative healthcare products for patients across the region, enhancing Abu Dhabi's role in global pharmaceutical supply chains.
Stanislas Brun, vice president of Etihad Cargo, said the company is committed to supporting Abu Dhabi's vision of becoming a global hub for healthcare and life sciences distribution.
"This MoU, in partnership with the Department of Health – Abu Dhabi, ADIO and KEZAD, is a major step towards enhancing the UAE's strategic importance in the global pharmaceutical supply chain and ensuring greater access to innovative healthcare products for patients in the region and beyond."
"We are closely working with the relevant stakeholders to ensure the development of our dedicated healthcare and life sciences PharmaLife product matches the industry and regulations requirements," he added.
The MoU was signed by Al Mannaei of DOH, Brun of Etihad Cargo and Mansoor Al Marar, vice president of Industrial Business Development at KEZAD Group, a subsidiary of AD Ports Group.
